Transgene Biotek Ltd.'s partnership with NiedlFree Technologies has the potential to revolutionize the way people with diabetes manage their condition. Oral insulin delivery could eliminate the need for painful injections and make it easier for people to adhere to their treatment plans. This could lead to improved health outcomes and a better quality of life for millions of people worldwide.

These drones will initially debut in the domestic market before expanding internationally. Tailored for precision farming, GIS mapping, aerial surveys, short-range cargo transportation, and military applications, these drones reflect the company's commitment to pushing the boundaries of Unmanned Aerial Vehicle (UAV) technology.

In a remarkable display of resilience, the company's stock has outperformed recent market turbulence, posting a 17 per cent gain as of October 30, 2023, solidifying its status as a multibagger with astounding returns of 119.68 per cent over the past year.

Shares of this company have given about 130 per cent returns in the last six months.

The company has delivered returns of 16 per cent over the past year and stellar returns of 140 per cent over the past 3 years. Moreover, the company has a ROCE of 13.2 per cent and a ROE of 10.1 per cent. 

The stock is up by over 25 per cent from its 52-week low of Rs 116.5 per share.

Shares of the company gained more than 7 per cent in the last six months.

The stock is up by 21 per cent from its 52-week low of Rs 281 per share.

The market capitalization of BSE-listed companies was Rs 3,22,50,00 crore or approx. Rs 322 lakh crore as of October 12, 2023. 

The shares of the company saw a spurt in volume by more than 1.81 times on BSE.